Senate passes landmark healthcare reform bill; FDA warns Ranbaxy unit on manufacturing plant;

> The U.S. Senate passed its version of healthcare reform at around 7 a.m. Thursday, clearing the way for difficult negotiations with the House. Report

> India's Ranbaxy Laboratories said its U.S. unit Ohm Laboratories received an FDA warning letter on violations of good manufacturing practices at a plant in Gloversville, N.Y. Report

> Former HHS Secretary Tommy G. Thompson was appointed to the board of Silver Spring-based United Therapeutics. Thompson, who also once served as governor of Wisconsin, will fill a newly created seat on the board when his appointment begins Jan. 1. Story

> Sanofi-Aventis' $1.9 billion bid for Chattem announced earlier this week was leaked in advance to two French investors who made $4.2 million making illegal insider trades, U.S. regulators claimed in a lawsuit. Report

> Sun Pharmaceutical Industries has announced that RiskMetrics Group's ISS Governance Services, a leading independent proxy advisory firm, recommended that shareholders of Taro Pharmaceutical Industries vote against Taro's board of director nominees for election or re-election as directors, as well as the indemnification proposal for its proposed external directors, in the upcoming Annual General Meeting of Taro's shareholders scheduled for December 31, 2009. Release

> Four plaintiffs filed a complaint Wednesday in Burke County alleging that the use of a Salix Pharmaceuticals drug led to kidney damage, their lawyers said in a news release. Story

> Shares in Amylin Pharmaceuticals dropped nearly 10 percent after the FDA asked it to conduct more safety studies on its diabetes drug Byetta, which has been linked to pancreatitis. Report

> Sanofi-Aventis' new heart drug Multaq failed to win early support from the U.K.'s cost-effectiveness agency NICE. Report

> Bristol-Myers Squibb lowered its 2009 outlook to reflect the completion of its spinoff of Mead Johnson Nutrition. Report

> Abbott Laboratories, which is challenging a $1.67 billion patent verdict won by Johnson & Johnson over the arthritis medicine Humira, settled a royalty battle with the University of Iowa on the drug. Report

> Pfizer's Wyeth unit failed to persuade a British Columbia appeals court to dismiss a lawsuit alleging the menopause drug Premarin caused breast cancer. Report

> A Pennsylvania employee benefit fund lost its suit faulting Eli Lilly's marketing of the antipsychotic drug Zyprexa. Report

> FDA again rejected an additional use for Pfizer's Lyrica as a treatment for generalized anxiety disorder. Report

> Teva Pharmaceutical Industries today said Teva-KOWA Pharma, its joint venture in Japan with KOWA Company, has signed a definitive agreement to acquire a majority of the outstanding shares of Japanese generic pharmaceutical company Taisho Pharmaceutical Industries. Story

> New research suggests that myhrr--one of the wise men's gifts--may help lower bad cholesterol. Report

Biotech's year in review

> Economic disaster followed by a revival in biotech share prices. Report

> Dealmaking in biotech reaches fever pitch at end of 2009. Story

> Big Pharma upends its R&D empires with a frenzy of late-year deals. Report

> The genetic revolution takes aim at the pipeline. Story

> Congress prepares to deliver for biotechnology with healthcare reform. Report

 > Special Reports of 2009
    > Top 10 Layoffs of 2009
    > Top 15 Women in Pharma
    > The Top 12 GMP Violations
    > The 2009 Biotech Graveyard
    > Top Venture Capital Firms
    > FierceBiotech's 2009 Fierce 15
    > CEO pay of 2008: Who makes what in Big Biotech?
    > Top 5 Regions Targeting Biotech Companies - 2009
    > Top 15 Big Pharma Paychecks of 2008

And Finally... A gene linked to asthma susceptibility in children has been identified that may reveal its link to allergies and lead to new treatments. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.